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Background: Dyslipidemia is an important but modiﬁable risk factor of cardiovascular disease (CVD).
However, no nationwide registry has been designed so far to document the inter-relationship between
long-term clinical outcomes and the lipid control, and the use of lipid-lowering agents for secondary
prevention of cardiovascular events in patients with established CVD in a large representative sample of
public and private hospitals in Taiwan.
Methods: In this registry-type prospective observational study, we sought to record information with
regard to the secondary prevention of patients with stable symptomatic atherosclerotic disease, classi-
ﬁed by the presence of one of the following conditions: evidence of coronary artery disease, cerebro-
vascular disease, or peripheral vascular disease, focusing on lipid management, and long-term outcomes.
The data on customary Taiwanese clinical practice applied to outpatients will be collected from 14
centers across Taiwan, including public and private hospitals, and will be clinically followed for 5 years
after their inclusion.
Results: The analysis of this multicenter registry will demonstrate the treatment patterns, goal attain-
ment, factors inﬂuencing treatment, and the clinical outcomes among patients suffering from CVD in
Taiwan.
Conclusions: The registry may increase our understanding of the prevalence and consequences of athe-
rothrombosis on a nationwide basis. In addition to academic interests, the results may have impact on
future clinical practice pattern and national policy on lipid management in Taiwan.
Copyright  2012, Taiwan Society of Geriatric Emergency & Critical Care Medicine. Published by Elsevier
Taiwan LLC. All rights reserved.1. Introduction
Cardiovascular disease (CVD), including coronary heart disease
(CHD) and stroke, is the leading cause of disability and mortality in
both gender, not just in Taiwan but throughout the world1e4. The
rapid growth of CVD and CHD represents one of the most relevant
public health issues today4,5.erest.
ent of Medical Research and
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vention for patients with
gators.
iwan Society of Geriatric EmergenDyslipidemia has long been recognized as the most important
risk factor in the development of atherosclerosis in humans. In
Taiwan, the rates of occurrence for hypercholesterolemia and
hypertriglyceridemia have increased over the past 20 years6e8.
Moreover, low serum high-density lipoproteinecholesterol (HDL-
C) was determined to be an isolated and independent coronary risk
factor among a recognizable portion of Taiwanese population9.
To reduce the risk of CVD, most clinicians recognize the
importance of reducing low-density lipoproteinecholesterol (LDL-
C) levels10,11. Furthermore, many large trials and meta-analyses
have consistently demonstrated that statin therapy signiﬁcantly
reduces LDL-C levels and subsequently the incidence of cardio-
vascular events10e15. In fact, the current lipid management guide-
lines also recommend statins as the ﬁrst-choice medication for
reducing LDL-C levels16e19. However, despite their therapeutic
efﬁcacy, statins have not entirely eliminated the risk posed by CVD.cy & Critical Care Medicine. Published by Elsevier Taiwan LLC. All rights reserved.
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HDL-C and elevated triglyceride (TG) levels, a condition termed as
“atherogenic dyslipidemia”20e22. Clinical and epidemiologic data
illustrate the need to expand the scope of therapies to reduce the
residual cardiovascular risk associated with low HDL-C levels and
elevated TG levels, even when LDL-C levels are managed success-
fully23e26.
However, from the limited data published in the past few years,
based on the National Cholesterol Education Program Adult
Treatment Panel III (ATP III) in Taiwanese patients, irrespective of
receiving primary or secondary prevention therapy, the LDL-C goal
attainment was still unsatisfactory27e33. Most importantly, the
outcome study results produced insufﬁcient data with regard to
lipid control in Taiwanese population. It is thus necessary to orga-
nize rational and balanced guidelines for the management of
hyperlipidemia in Taiwan, based on our local epidemiological,
clinical, and basic research data. This is because almost all of the
large-scale clinical trials on lipid management to date were con-
ducted using Caucasian populations, and no extensive end-point
research and lipid-lowering therapy in Asians have been published.
Therefore, this study attempts to register and follow-up a large
population of patients receiving secondary prevention therapy for
CVD so as to deﬁne the current status of lipid-lowering therapy in
Taiwan, and the effects of lipid-lowering therapy on CVDmorbidity
and mortality.
2. Materials and methods
The Taiwanese Secondary Prevention for patients with
AtheRosCLErotic disease (T-SPARCLE) Registry represents a docu-
mentation project about the current clinical practice of caring for
patients with established CVD, focusing on lipid management in
medical centers across all regions in Taiwan, including public and
private hospitals, academic medical centers, and regional hospitals.
2.1. Design
The cross-sectional observational registry is intended to docu-
ment the clinical practice of managing patients with stable symp-
tomatic atherosclerotic disease in Taiwan. The medications
prescribed will be at the discretion of the primary treating physi-
cians; in addition, the patient or the physician will be free to
withdraw from the registry at any time, for any reason. There will
be also a longitudinal follow-up of these patients for 5 years.
2.2. Eligibility and inclusion criteria
This study will be a multicenter registry facilitated by at least 50
cardiologists, diabetologists, neurologists, or nephrologists. Poten-
tially eligible patients will be invited for a screening visit, where
nonprobability sampling will be applied, including consecutive
patients who meet eligibility criteria.
A total of 5000 male and female patients with stable symp-
tomatic atherosclerotic disease under 18 years of age will be
enrolled from the 14 participating sites. The deﬁnition of coronary
atherosclerosis will be the presence of signiﬁcant coronary artery
occlusion >50% in diameter, which is identiﬁed by a cardiac cath-
eterization examination, having a history of myocardial infarction
(MI) as evidenced by electrocardiography or hospitalization, or
angina with ischemic changes or positive response to stress test.
Patients with cerebral vascular disease, deﬁned as cerebral infarc-
tion, intracerebral hemorrhage (excluding intracerebral hemor-
rhage associated with trauma or other diseases), and transient
ischemic attack whose ultrasound conﬁrms atheromatous change
with >70% blockage in the carotid artery, will be included.Peripheral atherosclerosis with symptoms of ischemia and
conﬁrmed by ankle-brachial index, Doppler ultrasound, or angi-
ography will also be included.
2.3. Exclusion criteria
The main exclusion criteria will be refusal to provide necessary
informed consent, neurocognitive or psychiatric condition which
prevents in obtaining reliable clinical data (as judged by investi-
gators), life expectancy of <6 months (e.g., malignant metastatic
neoplasm), hemodynamically signiﬁcant valvular or congenital
heart disease, treatment with immunosuppressive agents, or any
other condition or situation which, in the opinion of the investi-
gator, was deemed to be unsuitable for this registration. Patients
will not be allowed to participate if they have experienced an acute
stroke, acute MI, acute coronary syndrome, or coronary revascu-
larization procedure within the last 3 months, or have been
scheduled to undergo coronary bypass graft surgery or valvular
surgery before study enrollment.
2.4. Study protocol
All potential patients will be screened for eligibility based on
their screening visit. Those who fulﬁll the inclusion criteria at the
screening visit will be invited to join the registry study.
Regular patient follow-upwill take place at the 6th,12th, and 18th
month, and every year thereafter for a total of 5 years through
clinical visits, follow-up phone calls, or record review from the
National Health Insurance Bureau (NHIB) of Taiwan.
At every clinical visit, vital signs, clinical end points, adverse
events, concurrent medication information, and laboratory speci-
mens will be obtained as thoroughly as possible; however, when
phone calls or records from NHIB are involved, only clinical end
points will be recorded. The lipid proﬁle (total cholesterol, HDL-C,
TG), liver enzymes, and creatine phosphokinase levels will be
evaluated at baseline, and every year thereafter. While addressing
the lipid control and other medical needs of the study patients, the
investigators will follow the recommendations from the NHIB
regarding lipid-lowering guidelines. If the primary treating physi-
cian intends to treat the patient’s lipid proﬁle to the target, he/she
can add, remove, or adjust the lipid-lowering drugs according to
his/her clinical judgment.
The registry will also record concomitant secondary prevention
interventions with proven beneﬁts, including aspirin, statins,
angiotensin-converting enzyme inhibitors or angiotensin receptor
blockers, smoking cessation, physical activity, and healthy nutri-
tional guidelines.
2.5. Outcomes
The primary objective of this trial is to register the time of ﬁrst
occurrence of a major cardiovascular event, deﬁned as cardiovas-
cular death, hospitalization for nonfatal MI or stroke, or cardiac
arrest with resuscitation in patients receiving secondary preven-
tion therapy over a period of 5 years.
There will be two prespeciﬁed composite secondary outcomes:
(1) any CHD event (coronary death or hospitalization for nonfatal
MI, any coronary revascularization procedure, or hospitalization for
unstable angina); (2) any cardiovascular events (any major
cardiovascular events plus hospitalization for any revascularization
procedure, unstable angina, congestive heart failure, nonfatal
stroke, or peripheral arterial disease, deﬁned as a new clinical
diagnosis or hospitalization for such disease). In addition, indi-
vidual components of the composite end points will be prespeciﬁed
as secondary outcomes, and thus will be all-cause mortality.
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change, myopathy, or liver enzyme change after the lipid-lowering
therapy. In addition, we will measure the proportion of patients
receiving secondary prevention interventions recommended by
treatment guidelines, and evaluate the impacts of different
secondary prevention interventions and their adherence on late
outcomes.2.6. Sample calculation
In order to detect a proportion of 25% for the occurrence of the
primary outcome in 5 years, considering a sampling error of 2%, an
alpha of 5%, and a statistical power of 80%, at least 3300 patients
must be included. Our sample size will manifestly be sufﬁcient to
meet the primary objectives of the study.2.7. Statistical analysis
Quantitative variables will be expressed as mean and standard
deviation in the presence of normal or median distribution, and
interquartile range in the presence of asymmetric distribution.
Qualitative variables will be presented in both absolute frequencies
(number of patients) and relative frequencies (percentage).
The primary, secondary, and tertiary outcomes will be described
by an overall percentage, taking all centers into consideration, and
the percentage prescribed in each center. These will also be
expressed by means of proportions and their conﬁdence intervals
of 95%. Where there is great variability in prescription, a weighted
average variance at each center will be generated.
For regression models, we will report the odds ratio (logistic
regression) or hazard ratio (for the regression of Cox proportional
hazards), the corresponding standard error, the conﬁdence inter-
vals of 95%, and p values.
Additionally, we will report the p values up to three decimals;
however, places with p values below 0.001 are reported as
p < 0.001. In all the tests, we will use the two-tailed alpha signiﬁ-
cance level ¼ 0.05.2.8. Quality control and data management
For study data quality control, the following strategies will be
used: initial classroom training, electronic case report form, central
check of data, and tutoring.2.9. Ethical considerations
The study will be approved by the institutional review board of
each participating site, and written informed consent will be ob-
tained from all patients. The clinical trial will be conducted in
accordance with the principles of the current revision of the
Declaration of Helsinki and the latest version of the Guidelines for
Good Clinical Practice (ICH-GCP), and the study will be performed
according to those local and regulatory legal requirements
enforceable in Taiwan.2.10. Data collection
Patient inclusion was initiated on December 9, 2009 at 14
participating centers and by February 9, 2011, 3486 patients had
been included. The 1st year follow-up of the patients should be
completed by the end of the 2nd quarter of 2012.3. Discussion
Individuals presenting with any atherosclerotic disease for the
ﬁrst time are at risk of subsequent vascular events; for example,
MI and stroke, two major manifestations of atherothrombosis,
which are characterized by increasing incidence rates and require
special attention in the future because of their increased asso-
ciation with morbidity, and the high socioeconomic burden they
can cause3,5,27,33e35. Consequently, there is a need to develop
strategies to prevent either the primary development of these
clinical diseases, or to offer therapeutic interventions that can
effectively lower long-term event rates in these vulnerable
populations.
Lowering of LDL-C with statins has, in the last decade, become
a part of the standard treatment for patients with hyperlipid-
emia10,11. Secondary and primary prevention trials have demon-
strated that lipid lowering with a statin drug can dramatically and
cost effectively reduce CHD morbidity and mortality with no
increase in noncardiovascular mortality10e15,36e40. In 2001, while
the newly released ATP III maintained a focus on intensive treat-
ment of patients with CHD, its major new feature underscored the
need for primary prevention in persons withmultiple risk factors16.
Afterwards, The Heart Protection Study, the largest lipid-lowering
study to date including a wide range of high-risk patients
covering both primary and secondary prevention, demonstrated
striking lipid-lowering beneﬁts by administering simvastatin
compared with placebo41. The Anglo-Scandinavian Cardiac
Outcomes Trial-Lipid Lowering Arm study that assessed the bene-
ﬁts of lowering cholesterol levels in the primary prevention of CHD
had also clearly demonstrated a large reduction in major cardio-
vascular events by administering a dose atorvastatin within a short
treatment period42.
More recently, the Treating to New Targets study comparing
high and low doses of atorvastatin in stable nonacute patients
with CHD documented a signiﬁcant improvement in prognosis
with respect to CVD43. Hence, in 2004, the updated ATP III intro-
duced a new target of <70 mg/dL (1.8 mmol/L) for patients with
established CVD and at a very-high risk category17. Since then, the
Incremental Decrease in End Points Through Aggressive Lipid
Lowering study with intensive lowering of LDL-C with atorvasta-
tin using the highest recommended dose had yielded an incre-
mental beneﬁt compared with the moderate, most widely used
dose of simvastatin44. The latest Cholesterol Treatment Trialists’
Collaboration Study, a prospective meta-analysis, further
conﬁrmed the efﬁcacy and safety of more intensive lowering of
LDL-C15. To sum up, statins are the ﬁrst-choice medication for
reducing LDL-C levels, and clinical trials have demonstrated
beyond any doubt that lowering LDL-C levels with statins
considerably diminishes the risk of CVD in a wide range of
patients. It is not surprising, therefore, that the new 2011 Euro-
pean Guidelines for the Management of Dyslipidemia recommend
the use of statin monotherapy up to the highest recommended
dose, or highest tolerable dose to reach the target level. Currently,
it is the only Class I Level A evidence-based pharmacological
treatment for hypercholesterolemia19.
Statin therapy, moreover, has the greatest efﬁcacy in the pres-
ence of inﬂammation; several studies have already shown that
statins reduce the inﬂammatory biomarker high-sensitivity C-
reactive protein largely independent of LDL-C45e49. These ﬁndings
are consistent with the pathophysiological understanding that
atherothrombosis is a disorder of both hyperlipidemia and
inﬂammation, and that statins have anti-inﬂammatory and lipid-
lowering properties.
Other lipid-lowering drugs (e.g., ﬁbrates) may also reduce the
number of cardiovascular events in high-risk patients20e26. Fibrates
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demia, because of their beneﬁcial effects in reducing high TG and
increasing the low HDL-C levels, the characteristic lipid abnor-
malities commonly seen in patients with diabetes or metabolic
syndrome23e26. In the Veterans Affairs High-Density Lipoprotein
Cholesterol Intervention Trial study, after a median follow-up of 5.1
years, administration of gemﬁbrozil, compared with placebo,
resulted in a signiﬁcant relative reduction (about 22%) of the
primary event (nonfatal MI or death from coronary causes) in 2531
men with CHD whose HDL cholesterol levels were 40 mg/dL
(1.0 mmol/L), and LDL cholesterol levels were 140 mg/dL
(3.6 mmol/L)23. In the Fenoﬁbrate Intervention and Event Lowering
in Diabetes study, the use of fenoﬁbrate did not signiﬁcantly reduce
the risk of the primary outcome of coronary events (CHD death or
nonfatal MI) in 9795 participants with type 2 diabetes mellitus.
However, it signiﬁcantly reduced total cardiovascular events,
mainly due to fewer nonfatal MI and revascularizations24.
During the last decade, practice guidelines have become an
important component of secondary prevention and the manage-
ment of CVD16e19. The current guidelines emphasize that appro-
priate use of risk-reducing pharmacotherapies proffers a major
opportunity for reducing events, during both outpatient visits and
discharge after hospitalization for acute ischemic events16e19.
However, the LDL-C goal attainment based on the ATP III goals in
Taiwanese patients was still unsatisfactory, irrespective of any
primary or secondary prevention methods that were used27e33.
Although these results indicate that lipid-lowering therapy has
been applied much more successfully in recent years than it was
a decade ago, there is still substantial room for improvement,
particularly in very high-risk patients with established CVD.
Moreover, an extensive study regarding clinical outcomes in rela-
tion to lipid control in Taiwan is yet to be conducted. Those
conclusions regarding the clinical beneﬁts of lipid-lowering
therapy are to date primarily drawn from large-scale clinical trials
conducted almost exclusively in Caucasian populations. The
T-SPARCLE Registry thus provides an opportunity to evaluate
whether application of treatment guidelines is effective in reducing
ischemic events because the database contains data on long-term
risk-reduction interventions. We hypothesize that different
ischemic event rates may be observed in those patients in whom
guidelines are frequently adhered to, as compared with patients
who fail to follow these guidelines diligently. We expect that the
results of this study may have a major impact on future clinical
practice patterns and national policy on lipid management in
Taiwan.
Furthermore, given the current concept of cardiovascular
prevention, it is more important to classify patients in terms of the
cardiovascular risk presented by their diseases, as opposed to just
classifying them as having diabetes mellitus, hypertension, or
dyslipidemia16e19. Risk factors may have different effects on the
various manifestations of atherothrombosis. For example, despite
the fact that stroke and MI are both manifestations of atheroscle-
rosis, high blood pressure is a more relevant risk for stroke;
whereas elevated cholesterol has more relevance to risk for CHD
events2,9,50. Therefore, prevention based on the concept of cardio-
vascular risk means guiding prevention efforts not in terms of risks
attributable to the increase of isolated factors (such as blood
pressure or cholesterol), but in terms of the sum of all risks due to
multiple factors, estimated by the overall absolute risk in each
individual16e19. In view of this circumstance, the T-SPARCLE
Registry will provide an opportunity to gather important infor-
mation about the possible contribution of different risk factors on
the later development of vascular events, and gauge both the
ischemic event rates and the use of risk-reduction therapies in
a large Taiwanese population.3.1. Study limitations
Although this is a large registry of atherothrombotic disease
involving many regions in Taiwan, there are several noteworthy
limitations to our study. The enrollment of patients should be
consecutive, but because of the logistics involved on a nationwide
basis, it is not possible to ensure that this occurs with enrollment
logs, particularly in busy clinical practices. Nevertheless, the
enrollment at each site occurred at a rapid pace, suggesting that
only limited biases were introduced by not insuring absolute
consecutive patient enrollment. Moreover, the site selection should
be undertaken to reﬂect on the different patient management
practices followed for treating atherothrombotic diseases across
Taiwan. However, it was neither possible to randomize sites truly or
hospitals for this endeavor, nor was it possible for a community-
wide data collection. Because most of the patients with estab-
lished CVD are treated by hospital-based specialists, we did not
include general practitioners at local clinics in the registry.
However, we have indeed made every effort to include public and
private hospitals, academic medical centers as well as regional
hospitals, to ensure that a representative population and sites were
included in the T-SPARCLE Registry.
4. Conclusions
The T-SPARCLE Registry represents a signiﬁcant opportunity to
increase our understanding of the prevalence and consequences of
atherothrombosis on a nationwide basis in Taiwan. These data are
likely to offer an important opportunity to raise the awareness of
this disease among a wide range of physicians and other medical
professionals. It is also expected that the T-SPARCLE Registry may
demonstrate the need for improvement in current clinical
management standards, and will offer a cross-sectional database
that can serve as a baseline while we work to improve the
administration of methods to prevent and treat atherosclerotic
disease in Taiwan.
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Appendix
1.1. Organization
1.1.1. Main investigators: Wei-Hsian Yin, Chau-ChungWu, and Jaw-
Wen Chen
1.1.2. Steering committee: Wei-Hsian Yin, Chau-Chung Wu, Jaw-
Wen Chen, Yi-Heng Li, Hung-I Yeh, Ching-Chang Fang, Kuo-
Yang Wang, Tsung-Hsien Lin, Wei-Kung Tseng, Ai-Hsien Li,
Kwo-Chang Ueng, I-Chang Hsieh, Chiun-Hsiung Wang, Lien-
Chi Huang, Wen-Harn Pan
1.1.3. Coordination of the Institute for Teaching and Research:
Shao-Yuan Chuang, Yu-Hui Huang, Chin-Feng Cheng
1.1.4. Intellectual property: The Taiwan Society of Lipids and
Atherosclerosis
1.1.5. Coordination and supervision: The Taiwan Society of Lipids
and Atherosclerosis and Taiwan Consortium of Lipid and
Atherosclerosis
1.1.6. Research centers: National Cheng Kung University Hospital,
Tainan (Y.H.L.); Taipei Veterans General Hospital, Taipei (J.-
W.C.); Cheng-Hsin General Hospital, Taipei (W.-H.Y.);
National Taiwan University Hospital, Taipei (C.-C.W.); Mackay
Memorial Hospital, Taipei (H.-I.Y.); Tainan Municipal
Secondary Prevention of CVD in Taiwan 245Hospital, Tainan (C.-C.F.); Taichung Veterans General
Hospital, Taichung (K.-Y.W.); Kaohsiung Medical University
Chung-Ho Memorial Hospital, Kaohsiung (T.-H.L.); E-Da
Hospital, Kaohsiung (W.-K.T.); Far Eastern Memorial Hospital,
Taipei (A.-H.L.); Chung ShanMedical University, Taichung (K.-
C.U.); Linkou Chang Gung Memorial Hospital, Taipei (I.-C.H.);
Taipei City Hospital Renai Branch, Taipei (C.-H.W.); and Taipei
City Hospital Heping Fuyou Branch, Taipei (L.-C.H.); National
Health Research Institutes, Taiwan (W.-H.P.)
1.2. Publishing policy
All presentations of the study and/or publication of ﬁndings will
be based on clear evidence veriﬁed and validated in order to ensure
accurate results. Details concerning the responsibility and sequence
of these presentations and/or publications will be in accordance
with the Taiwan Society of Lipids and Atherosclerosis.
The authorship of publication of the main conclusions of this
studywill be decided by the contributions from the study centers in
general. All participants in the registry (investigators and
committee members included) should make an advance delegation
of authority to the Taiwan Society of Lipids and Atherosclerosis. Any
presentation or publication by any participant in the study should
acknowledge the above facts, and should obtain the approval of the
Taiwan Society of Lipids and Atherosclerosis.
1.3. Financing
This Registry is supported and owned by the Taiwan Society of
Lipids and Atherosclerosis using funds dedicated to this purpose for
its implementation.
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